Spectral Medical Announces Third Quarter Results and Provides Corporate Update

Tigris Trial Enrollment Reaches 76 Patients
Crude mortality results continue to exceed expectations

TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Read more at globenewswire.com